• 1
    Deber RB. Physicians in health care management: 7. The patient–physician partnership: changing roles and the desire for information. CMAJ. 1994; 151: 171176.
  • 2
    Deber RB. Physicians in health care management: 8. The patient–physician partnership: decision making, problem solving and the desire to participate. CMAJ. 1994; 151: 423427.
  • 3
    Eddy DM. Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA. 1990; 263: 3077, 3081, 3084.
  • 4
    O'Connor AM, Fiset V, Degrasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr. 1999; 6780.
  • 5
    O'Connor AM, Rostom A, Fiset V, et al. Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ. 1999; 319: 731734.
  • 6
    Barry MJ, Cherkin DC, Chang Y, et al. A randomized trial of a multimedia shared decision-making program for men facing a treatment decision for benign prostatic hyperplasia. Dis Manag Clin Outcomes. 1997; 1: 514.
  • 7
    Fallowfield LJ, Hall A, Maguire GP, et al. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ. 1990; 301: 575580.
  • 8
    Llewellyn-Thomas HA, Thiel EC, Clark RM. Patients versus surrogates: whose opinion counts on ethics review panels? Clin Res. 1989; 37: 501505.
  • 9
    Llewellyn-Thomas HA. Investigating patients' preferences for different treatment options. Can J Nurs Res. 1997; 29: 4564.
  • 10
    Dales RE, O'Connor A, Hebert P, et al. Intubation and mechanical ventilation for COPD: development of an instrument to elicit patient preferences. Chest. 1999; 116: 792800.
  • 11
    Llewellyn-Thomas H, Thiel E, Paterson M, et al. In the queue for coronary artery bypass grafting: patients' perceptions of risk and ‘maximal acceptable waiting time.’ J Health Serv Res Policy. 1999; 4: 6572.
  • 12
    Llewellyn-Thomas HA, Arshinoff R, Bell M, et al. In the queue for total joint replacement: patients' perspectives on waiting times. Ontario Hip and Knee Replacement Project Team. J Eval Clin Pract. 1998; 4: 6374.
    Direct Link:
  • 13
    Llewellyn-Thomas HA, Paterson JM, Carter JA, et al. Primary prevention drug therapy: can it meet patients' requirements for reduced risk? Med Decis Making. 2002; 22: 326339.
  • 14
    Palda VA, Llewellyn-Thomas HA, Mackenzie RG, et al. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol. 1997; 15: 31923200.
  • 15
    Percy ME, Llewellyn-Thomas H. Assessing preferences about the DNR order: does it depend on how you ask? Med Decis Making. 1995; 15: 209216.
  • 16
    Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997; 15: 330340.
  • 17
    Brundage MD, Davidson JR, Mackillop WJ, et al. Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. Med Decis Making. 1998; 18: 256267.
  • 18
    Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980; 1: 514.
  • 19
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106: 287296.
  • 20
    Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, et al. Describing health states. Methodologic issues in obtaining values for health states. Med Care. 1984; 22: 543-552.
  • 21
    McNeil BJ, Pauker SG, Sox HC Jr, et al. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982; 306: 12591262.
  • 22
    McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995; 109: 404413.
  • 23
    Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997; 113: 14651473.
  • 24
    Belluzzi A, Campieri M, Belloli C, et al. A new enteric coated preparation of omega-3-fatty-acids for preventing post-surgical recurrence in Crohn's disease. Gastroenterology. 1997; 112: A930.
  • 25
    Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology. 1999; 116: 294300.
  • 26
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995; 108: 16171621.
  • 27
    Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004; 127: 723729.
  • 28
    Green SB, Salkind NJ, Akey TM. Using SPSS for Windows. Analyzing and understanding data. Upper Saddle River, NJ: Prentice-Hall; 1997.
  • 29
    Rosner B. Fundamentals of Biostatistics. 4th ed. Duxbury Press, division of Thomson Publishing Inc.; 1995.
  • 30
    Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004; 22: 714724.
  • 31
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 10291035.
  • 32
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761769.
  • 33
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000; 118: 10181024.
  • 34
    Kennedy ED, To T, Detsky AS, et al. Azathioprine, methotrexate, remicade or surgery in chronic active Crohn's disease—what do patients prefer? Gastroenterology. 2001; 120: A624.
  • 35
    Schreiber S, Hamling J, Wedel S, Nikolaus SN, Buhr HJ, Raedler A. Efficacy of patient education in chronic inflammatory bowel disease in a prospective controlled multicentre trial. Gastroenterology.. 1999; 116: G3535.
  • 36
    Meuwissen SG, Ewe K, Gassull MA, et al. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000; 12: 1318.
  • 37
    Hilsden RJ, Verhoef MJ, Best A, et al. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol. 2003; 3: 10.
  • 38
    Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98: 15351544.
    Direct Link: